{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:18:47Z","timestamp":1791137927639,"version":"4.1.0"},"reference-count":78,"publisher":"American Psychiatric Association Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2005,2,1]]},"DOI":"10.1176\/appi.ajp.162.2.340","type":"journal-article","created":{"date-parts":[[2005,1,27]],"date-time":"2005-01-27T23:18:39Z","timestamp":1106867919000},"page":"340-349","source":"Crossref","is-referenced-by-count":114,"title":["Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence"],"prefix":"10.1176","volume":"162","author":[{"given":"Richard S.","family":"Schottenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek C.","family":"Chawarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana R.","family":"Pakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Pantalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"R1622BABGEJAA","doi-asserted-by":"crossref","unstructured":"Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML: Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995; 119:268\u2013276","DOI":"10.1007\/BF02246290"},{"key":"atypb1","unstructured":"Walsh SL, Preston KL, Bigelow GE, Stitzer ML: Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274:361\u2013372"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40:27\u201335","DOI":"10.1016\/0376-8716(95)01189-7"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290\u20131297","DOI":"10.1056\/NEJM200011023431802"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE: A placebo controlled trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17\u201325","DOI":"10.1016\/0376-8716(95)01186-2"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Schottenfeld RS, Pakes J, O\u2019Connor P, Chawarski M, Oliveto A, Kosten TR: Thrice-weekly versus daily buprenorphine maintenance. Biol Psychiatry 2000; 47:1072\u20131079","DOI":"10.1016\/S0006-3223(99)00270-X"},{"key":"atypb6","doi-asserted-by":"crossref","unstructured":"Bickel WK, Amass L, Crean JP, Badger GJ: Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999; 146:111\u2013118","DOI":"10.1007\/s002130051096"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Comer SD, Collins ED: Self-administration of intravenous buprenorphine and the buprenorphine\/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002; 303:695\u2013703","DOI":"10.1124\/jpet.102.038141"},{"key":"atypb9","unstructured":"Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML: Buprenorphine\u2019s physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 1996; 276:449\u2013459"},{"key":"atypb10","doi-asserted-by":"crossref","unstructured":"Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN: Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998; 50:1\u20138","DOI":"10.1016\/S0376-8716(98)00008-8"},{"key":"atypb11","doi-asserted-by":"crossref","unstructured":"Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J: Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 2000; 61:85\u201394","DOI":"10.1016\/S0376-8716(00)00126-5"},{"key":"atypb12","doi-asserted-by":"crossref","unstructured":"Mendelson J, Jones RT, Welm S, Brown J, Batki SL: Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 1997; 41:1095\u20131101","DOI":"10.1016\/S0006-3223(96)00266-1"},{"key":"atypb13","doi-asserted-by":"crossref","unstructured":"Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP: Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 1999; 141:37\u201346","DOI":"10.1007\/s002130050804"},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"Preston KL, Bigelow GE, Liebson IA: Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 1988; 94:484\u2013490","DOI":"10.1007\/BF00212842"},{"key":"atypb15","doi-asserted-by":"crossref","unstructured":"Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE: Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 1992; 30:263\u2013274","DOI":"10.1016\/0376-8716(92)90061-G"},{"key":"R1622BABDFBJF","doi-asserted-by":"crossref","unstructured":"Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D (Buprenorphine\/Naloxone Collaborative Study Group): Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949\u2013958","DOI":"10.1056\/NEJMoa022164"},{"key":"R1622BABFAAJI","doi-asserted-by":"crossref","unstructured":"Leri F, Bruneau J, Stewart J: Understanding polydrug use: review of heroin and cocaine co-use. Addiction 2003; 98:7\u201322","DOI":"10.1046\/j.1360-0443.2003.00236.x"},{"key":"R1622BABIEFIJ","doi-asserted-by":"crossref","unstructured":"Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM: Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997; 11:261\u2013278","DOI":"10.1037\/\/0893-164X.11.4.261"},{"key":"R1622BABBEJCA","doi-asserted-by":"crossref","unstructured":"Wasserman DA, Weinstein MG, Havassy BE, Hall SM: Factors associated with lapses to heroin use during methadone maintenance. Drug Alcohol Depend 1998; 52:183\u2013192","DOI":"10.1016\/S0376-8716(98)00092-1"},{"key":"R1622BABGBBDD","doi-asserted-by":"crossref","unstructured":"Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR: Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989; 261:561\u2013565","DOI":"10.1001\/jama.261.4.561"},{"key":"atypb16","doi-asserted-by":"crossref","unstructured":"Joe GW, Simpson DD: HIV risks, gender, and cocaine use among opiate users. Drug Alcohol Depend 1995; 37:23\u201328","DOI":"10.1016\/0376-8716(94)01030-O"},{"key":"atypb17","doi-asserted-by":"crossref","unstructured":"Bux DA, Lamb RJ, Iguchi MY: Cocaine use and HIV risk behavior in methadone maintenance patients. Drug Alcohol Depend 1995; 37:29\u201335","DOI":"10.1016\/0376-8716(94)01058-S"},{"key":"R1622BABCHGGD","doi-asserted-by":"crossref","unstructured":"Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH: Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health 1995; 85:83\u201388","DOI":"10.2105\/AJPH.85.1.83"},{"key":"R1622BABIJFDA","doi-asserted-by":"crossref","unstructured":"Kolar AF, Brown BS, Weddington WW, Ball JC: A treatment crisis: cocaine use by clients in methadone maintenance programs. J Subst Abuse Treat 1990; 7:101\u2013107","DOI":"10.1016\/0740-5472(90)90005-B"},{"key":"atypb18","doi-asserted-by":"crossref","unstructured":"Hunt D, Spunt B, Lipton D, Goldsmith D, Strug D: The costly bonus: cocaine related crime among methadone treatment clients. Adv Alcohol Subst Abuse 1986; 6:107\u2013122","DOI":"10.1300\/J251v06n02_08"},{"key":"atypb19","doi-asserted-by":"crossref","unstructured":"Kosten TR, Rounsaville BJ, Kleber HD: Antecedents and consequences of cocaine abuse among opioid addicts: a 2.5-year follow-up. J Nerv Ment Dis 1988; 176:176\u2013181","DOI":"10.1097\/00005053-198803000-00006"},{"key":"R1622BABIAHDD","doi-asserted-by":"crossref","unstructured":"Kosten TR, Rounsaville BJ, Kleber HD: A 2.5-year follow-up of cocaine use among treated opioid addicts: have our treatments helped? Arch Gen Psychiatry 1987; 44:281\u2013284","DOI":"10.1001\/archpsyc.1987.01800150101012"},{"key":"R1622BABHCFGG","doi-asserted-by":"crossref","unstructured":"de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M: Pharmacological treatment of cocaine dependence: a systematic review. Addiction 2002; 97:931\u2013949","DOI":"10.1046\/j.1360-0443.2002.00209.x"},{"key":"R1622BABEDFCJ","doi-asserted-by":"crossref","unstructured":"Hser YI, Anglin MD, Fletcher B: Comparative treatment effectiveness: effects of program modality and client drug dependence history on drug use reduction. J Subst Abuse Treat 1998; 15:513\u2013523","DOI":"10.1016\/S0740-5472(97)00308-5"},{"key":"R1622BABDCHJG","unstructured":"Foltin RW, Christiansen I, Levin FR, Fischman MW: Effects of single and multiple intravenous cocaine injections in humans maintained on methadone. J Pharmacol Exp Ther 1995; 275:38\u201347"},{"key":"atypb20","unstructured":"Foltin RW, Fischman MW: Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther 1996; 278:1153\u20131164"},{"key":"atypb21","doi-asserted-by":"crossref","unstructured":"Lukas SE, Mello NK, Drieze JM, Mendelson JH: Buprenorphine-induced alterations of cocaine\u2019s reinforcing effects in rhesus monkey: a dose-response analysis. Drug Alcohol Depend 1995; 40:87\u201398","DOI":"10.1016\/0376-8716(95)01195-1"},{"key":"R1622BABBIJDB","unstructured":"Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ: The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther 1992; 260:1185\u20131193"},{"key":"atypb22","doi-asserted-by":"crossref","unstructured":"Mello NK, Mendelson JH, Bree MP, Lukas SE: Buprenorphine suppresses cocaine self-administration by rhesus monkeys. Science 1989; 245:859\u2013862","DOI":"10.1126\/science.2772637"},{"key":"atypb23","unstructured":"Kosten TR, Rosen MI, Schottenfeld R, Ziedonis D: Buprenorphine for cocaine and opiate dependence. Psychopharmacol Bull 1992; 28:15\u201319"},{"key":"atypb24","doi-asserted-by":"crossref","unstructured":"Kosten TR, Kleber HD, Morgan C: Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989; 26:637\u2013639","DOI":"10.1016\/0006-3223(89)90090-5"},{"key":"R1622BABEADFA","doi-asserted-by":"crossref","unstructured":"Kosten TR, Kleber HD, Morgan C: Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci 1989; 44:887\u2013892","DOI":"10.1016\/0024-3205(89)90589-4"},{"key":"R1622BABDIIAG","doi-asserted-by":"crossref","unstructured":"Ling W, Wesson DR, Charuvastra C, Klett CJ: A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401\u2013407","DOI":"10.1001\/archpsyc.1996.01830050035005"},{"key":"atypb25","doi-asserted-by":"crossref","unstructured":"Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR: Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713\u2013720","DOI":"10.1001\/archpsyc.1997.01830200041006"},{"key":"atypb27","doi-asserted-by":"crossref","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151:1025\u20131030","DOI":"10.1176\/ajp.151.7.1025"},{"key":"R1622BABDGJBI","doi-asserted-by":"crossref","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116:401\u2013406","DOI":"10.1007\/BF02247469"},{"key":"R1622BABCJFJC","doi-asserted-by":"crossref","unstructured":"West SL, O\u2019Neal KK, Graham CW: A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000; 12:405\u2013414","DOI":"10.1016\/S0899-3289(01)00054-2"},{"key":"R1622BABDBGGA","doi-asserted-by":"crossref","unstructured":"Comer SD, Lac ST, Wyvell CL, Carroll ME: Combined effects of buprenorphine and a nondrug alternative reinforcer on IV cocaine self-administration in rats maintained under FR schedules. Psychopharmacology (Berl) 1996; 125:355\u2013360","DOI":"10.1007\/BF02246018"},{"key":"R1622BABGHBBD","doi-asserted-by":"crossref","unstructured":"Rodefer JS, Mattox AJ, Thompson SS, Carroll ME: Effects of buprenorphine and an alternative nondrug reinforcer, alone and in combination on smoked cocaine self-administration in monkeys. Drug Alcohol Depend 1997; 45:21\u201329","DOI":"10.1016\/S0376-8716(97)01341-0"},{"key":"R1622BABJGBEG","doi-asserted-by":"crossref","unstructured":"Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, Foerg F, Fenwick JW: A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry 1991; 148:1218\u20131224","DOI":"10.1176\/ajp.148.9.1218"},{"key":"R1622BABJFFEJ","doi-asserted-by":"crossref","unstructured":"Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G: Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry 1993; 150:763\u2013769","DOI":"10.1176\/ajp.150.5.763"},{"key":"atypb28","doi-asserted-by":"crossref","unstructured":"Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger GJ: Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry 1994; 51:568\u2013576","DOI":"10.1001\/archpsyc.1994.03950070060011"},{"key":"R1622BABFDCGC","doi-asserted-by":"crossref","unstructured":"Higgins ST, Wong CJ, Badger GJ, Ogden DE, Dantona RL: Contingent reinforcement increases cocaine abstinence during outpatient treatment and 1 year of follow-up. J Consult Clin Psychol 2000; 68:64\u201372","DOI":"10.1037\/\/0022-006X.68.1.64"},{"key":"R1622BABHHJHH","doi-asserted-by":"crossref","unstructured":"Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ: Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? Addiction 2004; 99:349\u2013360","DOI":"10.1111\/j.1360-0443.2003.00642.x"},{"key":"R1622BABCDJFA","doi-asserted-by":"crossref","unstructured":"Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, Preston KL: Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry 1996; 53:409\u2013415","DOI":"10.1001\/archpsyc.1996.01830050045007"},{"key":"atypb29","doi-asserted-by":"crossref","unstructured":"Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL: Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin Psychol 1998; 66:811\u2013824","DOI":"10.1037\/\/0022-006X.66.5.811"},{"key":"atypb30","doi-asserted-by":"crossref","unstructured":"Silverman K, Chutuape MA, Bigelow GE, Stitzer ML: Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl) 1999; 146:128\u2013138","DOI":"10.1007\/s002130051098"},{"key":"R1622BABDBJHI","doi-asserted-by":"crossref","unstructured":"Preston KL, Umbricht A, Wong CJ, Epstein DH: Shaping cocaine abstinence by successive approximation. J Consult Clin Psychol 2001; 69:643\u2013654","DOI":"10.1037\/\/0022-006X.69.4.643"},{"key":"R1622BABCFBDG","doi-asserted-by":"crossref","unstructured":"Rawson RA, Huber A, McCann M, Shoptaw S, Farabee D, Reiber C, Ling W: A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. Arch Gen Psychiatry 2002; 59:817\u2013824","DOI":"10.1001\/archpsyc.59.9.817"},{"key":"R1622BABECCDJ","doi-asserted-by":"crossref","unstructured":"Downey KK, Helmus TC, Schuster CR: Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Exp Clin Psychopharmacol 2000; 8:176\u2013184","DOI":"10.1037\/\/1064-1297.8.2.176"},{"key":"R1622BABJACEC","doi-asserted-by":"crossref","unstructured":"Piotrowski NA, Tusel DJ, Sees KL, Reilly PM, Banys P, Meek P, Hall SM: Contingency contracting with monetary reinforcers for abstinence from multiple drugs in a methadone program. Exp Clin Psychopharmacol 1999; 7:399\u2013411","DOI":"10.1037\/\/1064-1297.7.4.399"},{"key":"R1622BABEBEFG","doi-asserted-by":"crossref","unstructured":"Petry NM, Martin B: Low-cost contingency management for treating cocaine- and opioid-abusing methadone patients. J Consult Clin Psychol 2002; 70:398\u2013405","DOI":"10.1037\/\/0022-006X.70.2.398"},{"key":"R1622BABDAEGG","doi-asserted-by":"crossref","unstructured":"Margolin A, Avants SK, Rounsaville B, Kosten TR, Schottenfeld RS: Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes. J Psychoactive Drugs 1997; 29:205\u2013212","DOI":"10.1080\/02791072.1997.10400189"},{"key":"R1622BABBCJEB","doi-asserted-by":"crossref","unstructured":"Higgins ST, Badger GJ, Budney AJ: Initial abstinence and success in achieving longer term cocaine abstinence. Exp Clin Psychopharmacol 2000; 8:377\u2013386","DOI":"10.1037\/\/1064-1297.8.3.377"},{"key":"R1622BABBBHBH","doi-asserted-by":"crossref","unstructured":"Schottenfeld RS, Pantalon MV, Chawarski MC, Pakes J: Community reinforcement approach for combined opioid and cocaine dependence: patterns of engagement in alternative activities. J Subst Abuse Treat 2000; 18:255\u2013261","DOI":"10.1016\/S0740-5472(99)00062-8"},{"key":"R1622BABHHICH","doi-asserted-by":"crossref","unstructured":"Radloff LS, Teri L: Use of the Center for Epidemiological Studies Depression Scale with older adults. Clin Gerontol 1986; 5:119\u2013136","DOI":"10.1300\/J018v05n01_06"},{"key":"atypb31","doi-asserted-by":"crossref","unstructured":"Radloff LS: The use of the Center for Epidemiologic Studies Depression Scale in adolescents and young adults. J Youth Adolesc 1991; 20:149\u2013166","DOI":"10.1007\/BF01537606"},{"key":"R1622BABGHFJA","doi-asserted-by":"crossref","unstructured":"McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M: The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9:199\u2013213","DOI":"10.1016\/0740-5472(92)90062-S"},{"key":"atypb32","doi-asserted-by":"crossref","unstructured":"Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea MT, Imber SD, Sotsky SM, Watkins JT: Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993; 50:739\u2013750","DOI":"10.1001\/archpsyc.1993.01820210073009"},{"key":"atypb33","doi-asserted-by":"crossref","unstructured":"Strain EC, Bigelow GE, Liebson IA, Stitzer ML: Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000\u20131005","DOI":"10.1001\/jama.281.11.1000"},{"key":"atypb34","doi-asserted-by":"crossref","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23\u201327","DOI":"10.7326\/0003-4819-119-1-199307010-00004"},{"key":"atypb35","doi-asserted-by":"crossref","unstructured":"Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR: Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 1993; 34:66\u201374","DOI":"10.1016\/0006-3223(93)90258-F"},{"key":"atypb36","unstructured":"Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE: Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988; 247:47\u201353"},{"key":"atypb37","doi-asserted-by":"crossref","unstructured":"Mello NK, Mendelson JH: Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207:657\u2013659","DOI":"10.1126\/science.7352279"},{"key":"R1622BABCDCHJ","doi-asserted-by":"crossref","unstructured":"Mendelson J, Upton RA, Everhart ET, Jacob P III, Jones RT: Bioavailability of sublingual buprenorphine. J Clin Pharmacol 1997; 37:31\u201337","DOI":"10.1177\/009127009703700106"},{"key":"R1622BABBACJI","doi-asserted-by":"crossref","unstructured":"Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, Mendelson JE: Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 1999; 39:619\u2013623","DOI":"10.1177\/00912709922008236"},{"key":"R1622BABBCFFE","doi-asserted-by":"crossref","unstructured":"Dallery J, Silverman K, Chutuape MA, Bigelow GE, Stitzer ML: Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude. Exp Clin Psychopharmacol 2001; 9:317\u2013325","DOI":"10.1037\/1064-1297.9.3.317"},{"key":"R1622BABDHFAI","doi-asserted-by":"crossref","unstructured":"Milby JB, Schumacher JE, Wallace D, Frison S, McNamara C, Usdan S, Michael M: Day treatment with contingency management for cocaine abuse in homeless persons: 12-month follow-up. J Consult Clin Psychol 2003; 71:619\u2013621","DOI":"10.1037\/0022-006X.71.3.619"},{"key":"atypb38","doi-asserted-by":"crossref","unstructured":"Silverman K, Svikis D, Robles E, Stitzer ML, Bigelow GE: A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp Clin Psychopharmacol 2001; 9:14\u201323","DOI":"10.1037\/1064-1297.9.1.14"},{"key":"atypb39","doi-asserted-by":"crossref","unstructured":"Silverman K, Svikis D, Wong CJ, Hampton J, Stitzer ML, Bigelow GE: A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. Exp Clin Psychopharmacol 2002; 10:228\u2013240","DOI":"10.1037\/\/1064-1297.10.3.228"},{"key":"atypb40","doi-asserted-by":"crossref","unstructured":"Schumacher JE, Usdan S, Milby JB, Wallace D, McNamara C: Abstinent-contingent housing and treatment retention among crack-cocaine-dependent homeless persons. J Subst Abuse Treat 2000; 19:81\u201388","DOI":"10.1016\/S0740-5472(99)00089-6"},{"key":"R1622BABDEAIE","doi-asserted-by":"crossref","unstructured":"McLellan AT: Moving toward a \u201cthird generation\u201d of contingency management studies in the drug abuse treatment field: comment on Silverman et al (2001). Exp Clin Psychopharmacol 2001; 9:29\u201332","DOI":"10.1037\/\/1064-1297.9.1.29"},{"key":"R1622BABHBAHC","doi-asserted-by":"crossref","unstructured":"Preston KL, Umbricht A, Epstein DH: Abstinence reinforcement maintenance contingency and one-year follow-up. Drug Alcohol Depend 2002; 67:125\u2013137","DOI":"10.1016\/S0376-8716(02)00023-6"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.2.340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T01:21:53Z","timestamp":1721870513000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.162.2.340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2,1]]}},"alternative-id":["10.1176\/appi.ajp.162.2.340"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.162.2.340","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}